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Summary
Introduction Portal vein resection represents a viable
add-on option in standard pancreaticoduodenectomy
for locally advanced ductal pancreatic adenocarci-
noma, but is often underused as it may set patients
at additional risk for perioperative and postoperative
morbidity and mortality. We aimed to review our
long-term experience to determine the additive value
of this intervention for locally advanced pancreatic
adenocarcinoma.
Patients and methods Single, university surgical cen-
ter audit over a 13-year period; cohort comprised 221
consecutive patients undergoing pancreatic resection;
in 47 (21%) including portal vein resection. Predic-
tors for short- and long-term survival were assessed
via multivariate logistic and Cox regression.
Results Baseline and perioperative characteristics
were similar between the two groups. However, over-
all skin-to-skin times, intraoperative transfusion re-
quirements as the need for medical inotropic support
were higher in patients undergoing additional portal
vein resection (p < 0.0001; p = 0.001 and p = 0.03).
Postoperative complication rates were 34 vs. 35% (p =
0.89), 14 patients (5% vs. 11%; p = 0.18) died in-hos-
pital. An American Society of Anesthesiologists Score
>2 was the only independent predictor for in-hospital
mortality (OR 10.66, 95% CI 1.24–91.30). Follow-up
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was complete in 99.5 %, one-year survival was 59 %
vs. 70 % and five-year overall survival 15 % vs. 12 %
with and without portal vein resection, respectively
(Log rank: p = 0.25). For long-term outcome, mi-
crovascular invasion (HR 2.03, 95% CI 1.10–3.76) and
preoperative weight loss (HR 2.17, 95% CI 1.31–3.58)
were independent predictors.
Conclusion Despite locally advanced disease, patients
who underwent portal vein resection had no worse
perioperative and overall survival than patients with
lower staging and standard pancreaticoduodenec-
tomy only. Therefore, the feasibility of portal vein
resection should be evaluated in every potential can-
didate at risk.
Keywords Pancreatic ductal adenocarcinoma · Pan-
creaticoduodenectomy · Portal vein resection · Peri-
operative outcome · Long-term survival
Introduction
Complete surgical resection of pancreatic ductal
adenocarcinoma (PDAC) represents the key factor
for survival despite advances in chemo- and ra-
diochemotherapy. In the 1970s, Fortner first de-
scribed a radical en bloc surgical resection of venous
portal branches and surrounding tissues [1]. Despite
this approach might improve survival in locally ad-
vanced PDAC, surgeons often are concerned about
this technique in fear of the potential additional risk
for perioperative and postoperative morbidity and
mortality [2–5]. We aimed therefore to review our
long-term experience to determine the additional
value of portal venous resection in locally advanced
PDAC.




Single center, university surgical center audit over
a 13-year period; cohort compromised 221 consecu-
tive patients (112 females; median age 67 years [IQR
interquartile range(60–72)]) undergoing pancreatic re-
section for diagnosis of PDAC; in 47 (21%) portal vein
resection (PVR) has been performed as an add-on due
to locally advanced disease making a R0 resection im-
possible without additional resection of portal venous
tissue. Baseline and perioperative risk factors were
recorded; the ASA (American Association of Anesthe-
siologist’s) Score was applied to estimate the periop-
erative risk [6]. All eligible patients underwent a stan-
dardized preoperative screening program including
detailed physical examination including tumor mark-
ers carcino embryotic antigen (CEA), CA 19-9 (car-
bohydrate antigen) and liver function tests; preoper-
ative oncological staging comprised positron emis-
sion tomography (PET) scan, endoscopic retrograde
cholangiopancreaticography (ERCP) and/or magnetic
resonance cholangiopancreaticography (MRCP) and
esophagogastroduodenoscopy (EGD). If not already
performed at initial diagnosis, all patients received
a multidetector row computed tomography (MDCT)
with pancreas protocol. Prior to definite decision
for surgery all patients were admitted to the institu-
tional tumor board including surgeons, oncologists,
histopathologists, and radiologists. The institutional
review board approved the study and waived the need
for patient consent.
Portal vein resection technique
Depending on the primary tumor location, either
a standard or pylorus-preserving pancreaticoduo-
denectomy, distal pancreatectomy with splenectomy
or total pancreatectomy was carried out in all cases.
The biliodigestive anastomoses were connected with
5–0 or 6–0 double layer single sutures; the biliodi-
gestive anastomoses were performed routinely via
end-to-side pancreaticojejunostomy and hepaticoje-
junostomy and were protected by means of internal
drainages.
Portal vein resection was performed in all cases
of radiologic and/or intraoperative diagnosis of tu-
morous adherence or infiltration of the portal venous
wall, allowing a potential R0 resection with addi-
tional resection of the portal venous segment. Prior
to cross-clamp of the portal venous branches all pa-
tients received intravenously 5000 international units
(IU) heparin. In case that tumor infiltration of the
venous wall was less than one-third of the circum-
ference, this particular segment was resected in an
elliptic fashion and reconstructed with a Gore-tex®
patch; otherwise the affected vein segment was re-
sected completely: reconstruction of the portal axis
was achieved via a tension-free end-to-end anasto-
mosis with a continuous running 6–0 polypropylene
suture or via a Gore-tex® tube graft when a longer
vein segment had to be resected. Heparinization was
not reversed at the end of the procedure and contin-
ued intravenously until oral prescription of unlimited
aspirin or clopidogrel upon discretion of the surgeon.
Intraabdominal drainages were placed routinely in all
patients before closure of the abdominal wall.
Histopathological examination
Intraoperative rapid frozen section diagnosis was part
of the standard protocol and according to the intra-
operative histopathologic diagnosis, resection was ex-
tended until negative margins could be obtained or
the surgical strategy was switched to a total pancrea-
tectomy. In definitive histopathological examination,
a hematoxylin–eosin staining according to standard
procedures was performed, in cases with portal ve-
nous involvement, the grade of vascular infiltration
was differentiated between adhesion, adventitial, me-
dia, or transmural infiltration.
Follow-up protocol
Postoperative morbidity was classified according to
Clavien and Dindo (CDC) [7]. A drainage cholangiog-
raphy was performed in all patients before discharge
to exclude anastomotic leakage. Patients underwent
clinical, laboratory, and radiological (MDCT) follow-
up 3, 6, and 12 months postoperatively. Long-term
mortality data were obtained from the Austrian Na-
tional Cancer registry [8].
Statistical analysis
If not otherwise indicated, continuous variables were
reported as median and interquartile range; categor-
ical data were reported as count and percentages.
Categorical variables were compared with Fisher’s ex-
act text or the χ2 test, as appropriate; metric variables
were compared with the Wilcoxon test. A multivariate
logistic regression model was applied to assess the
strongest independent risk factor for intrahospital
mortality. Results of the statistic regression model are
given as the odds ratio (OR) and 95% confidence in-
terval (CI). A resampling model with 1000 replications
was then used to confirm CI. Regression diagnostics
and overall model fit were performed according to
standard procedures, providing Hosmer–Lemeshow
tests for calibration and C statistics for discrimination
of the final model. Overall survival and progression-
free survival were calculated according to the method
of Kaplan and Meier. A Cox regression model was
used for multivariate and univariate analysis to iden-
tify predictors for worse long-term outcome. A two-
sided p-value <0.05 was considered statistically sig-
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Table 1 Baseline andpreoperativedemographicpatient’s characteristics
Characteristics Overall (n = 221) Without portal vein resection (n = 174) With portal vein resection (n = 47) Two-sided p value
Demographic data
Age (years) 67 (60–72) 67 (60–73) 66 (60–71) 0.25
Female sex 112 (51%) 89 (51%) 23 (49%) 0.87
BMI 24 (22–28) 25 (22–28) 23 (22–26) 0.09
Age >70 years 75 (34%) 62 (36%) 13 (27%) 0.39
Chronic health conditions (%)
Alcohol abuse 19 (9) 14 (8) 5 (11) 0.57
Nicotine abuse 41 (19) 32 (19) 9 (19) 1.00
Chronic pancreatitis 27 (13) 22 (13) 5 (11) 1.00
Diabetes 60 (27) 48 (28) 12 (26) 0.86
Liver/renal cysts 9 (4) 7 (4) 2 (4) 1.00
ASA >2 133 (62) 109 (64) 24 (52) 0.17
Gastrointestinal comorbidity 43 (19) 33 (19) 10 (21) 0.68
Cardiovascular comorbidity 132 (60) 108 (62) 24 (51) 0.18
Pulmonary comorbidity 27 (12) 24 (14) 3 (6) 0.21
Other comorbidities 71 (34) 56 (34) 15 (34) 1.00
Extrapancreatic malignancy (current
and/or anamnestic)
36 (16) 28 (16) 8 (17) 1.00
Preoperative symptoms (%)
Emesis 22 (10) 17 (10) 5 (12) 0.78
Abdominal pain 107 (50) 83 (49) 24 (56) 0.50
Jaundice 64 (30) 50 (29) 14 (32) 0.72
Acute pancreatitis 27 (13) 20 (12) 7 (16) 0.44
Diarrhea 16 (8) 13 (8) 3 (7) 1.00
Weight loss 66 (30) 51 (30) 15 (32) 0.86
Preoperative diagnostics (%)
CT 176 (84) 137 (84) 39 (83) 0.83
MRI 122(59) 89 (55) 33 (70) 0.09
PET-CT 65 (31) 45 (28) 20 (46) 0.07
ERCP 85 (40) 63 (38) 22 (47) 0.31
PTCD 17 (8) 14 (8) 3 (6) 1.00
Radiol. tumor size (%)
<3 cm 82 (49) 61 (35) 21 (52) 0.23
3–5 cm 59 (36) 42 (33) 17 (29) 0.10
5–7 cm 17 (10) 16 (13) 1 (3) 0.08
>7 cm 6 (4) 5 (4) 1 (3) 0.21
Not available 63 (29)
Biopsy preop 25 (12) 18 (11) 7 (15) 0.45
Radiological portal venous infiltration 32 (14) 13 (7) 19 (47) <0.0001
BMI Body mass index, ASA Score Risk Score of the American Society of Anesthesiologists, CT Computed tomography, MRI Magnetic resonance imaging,
PET-CT positron emission tomography, ERCP endoscopic retrograde cholangiopancreaticography, PTCD percutaneous transhepatic cholangio-drainage
nificant and SPSS 22.0 for Windows (IBM Inc, Somers,
NY, USA) was used for all statistical analyses.
Results
Over a 13-year period, 221 consecutive patients
(112 females; median age 67 years [IQR 60–72]) were
subject to pancreatic resection for diagnosis of PDAC
at our institution; in 47 (21%) portal vein resection
was deemed necessary as an add-on due to locally
advanced disease.
Detailed demographics and cohort comparisons
are given in Tables 1 and 2: Baseline and perioperative
characteristics were similar between the two groups
without statistical significance except preoperative
finding of portal venous infiltration in radiological
imaging (p < 0.0001) Obviously due to the additional
procedure, overall skin-to skin times (median 361
[IQR 311–422] vs. 307 [IQR 236–361] minutes in pa-
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Table 2 Intra- andpostoperativepatient’s characteristics
Characteristics Overall (n = 221) Without portal vein resection (n = 174) With portal vein resection (n = 47) Two-sided p value
Intraoperative data
Skin-to-skin time (min) 318 (248–375) 307 (236–361) 361 (311–422) <0.0001
Kausch Whipple (%) 77 (35) 58 (33) 19 (40) 0.37
Pylorus preserving
pancreaticoduodenectomy (%)
65 (30) 54 (31) 11 (23) 0.31
Central resection (%) 1 (1) 1 (1) 0 0.60
Distal pancreatectomy (%) 47 (21) 40 (23) 7 (15) 0.23
Total pancreatectomy (%) 31 (14) 21 (12) 10 (21) 0.11
Splenectomy (%) 68 (32) 51 (29) 17 (36) 0.48
Internal drainage (%) 122 (58) 94 (54) 28 (60) 0.74
Intraoperative blood transfusion (%) 108 (62) 74 (55) 34 (85) 0.001
Intraoperative inotropic support (%) 37 (19) 23 (16) 14 (32) 0.03
Postoperative patient’s characteristics
ICU stay (days) 3 (2–5) 3 (2–4.5) 3 (2–5) 0.11
In-hospital stay (days) 24 (18–31) 23 (17–31) 25 (20–31) 0.23
Postoperative blood transfusion (%) 34 (18) 9 (5) 5 (11) 0.18
In-hospital mortality (%) 14 (6) 9 (5) 5 (11) 0.18
unless otherwise indicated, data are number (percentage), IQR interquartile range, ICU intensive care unit
Table 3 Histopathological details
Characteristics Overall (n = 221) Without portal vein resection (n = 174) With portal vein resection (n = 47) Two-sided p value
Histopathological data
Pancreatitis (%) 62 (30) 51 (32) 11 (24) 0.36
Perineural invasion (%) 49 (23) 36 (21) 13 (28) 0.32
Lymphovascular invasion (%) 105 (52) 79 (50) 26 (59) 0.31
R0 [dorsal margin <1 mm (%)] 106 (60) 87 (62) 19 (50) 0.24
R0 (%) 180 (87%) 141 (87%) 39 (89) 0.76
Lymph node ratio 0.16 (0.06–0.33) 0.16 (430.05–0.33) 0.13 (0.07–0.29) 0.43
Table 4 Details of portal vein infiltration




Tumor adherence 15 (32)
No specification 10 (21)
tient with and without PVR, respectively), transfusion
requirements (85 vs. 55% of patients) as the need for
medical inotropic support (32 vs. 16%) were higher
in patients undergoing additional portal vein resec-
tion (p < 0.0001; p = 0.001 and p = 0.03). Detailed
histopathological results were given in Tables 3 and 4.
Postoperative complication rates according to
Clavien and Dindo (CDC) were 34 vs. 35% (p = 0.89),
and 14 patients (5 vs. 11%; p = 0.18) died in-hospital.
An ASA Score >2 was the only independent predictor
for in-hospital mortality in logistic regression analysis
(OR 10.66, 95% CI 1.24–91.30; H/L = 0.73, c-statistics:
p = 0.79). The strong influence of an ASA Score >2 on
in-hospital mortality could be confirmed in bootstrap
analysis (95% CI 1.04–22.12; Table 5).
Table 5 Resultsofunivariate logistic regressionanalysisof
in-hospitalmortality concerning selectedpotential predic-
tors’
Risk factor OR* (95% CI**) Two-sided p-value
Sex 0.35 (0.08–1.53) 0.16
Age >70 years 1.43 (0.36–5.68) 0.61
Alcohol abuse 1.34 (0.21–8.49) 0.76
Diabetes mellitus 0.26 (0.05–1.47) 0.13
ASA Score> II 10.66 (1.24–91.30) 0.03
Preop. weight loss 0.80 (0.18–3.52) 0.77
Preop. jaundice 1.08 (0.25–4.66) 0.92
Preop. pancreatitis 1.05 (0.17–6.37) 0.96
ERCP preop 0.67 (0.16–2.79) 0.58
UICC > II 3.90 (0.58–26.25) 016
PVR 2.31 (0.57–9.34) 0.24
OR Odds ratio, CI Confidence interval, ASA Score Anesthesiologic risk score
of the American society of anesthesiology, ERCP Endoscopic retrograde
cholangiopancreaticography, UICC Union Internationale contre la Cancer;
clinical tumor stage, PVR portal vein resection
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Table 6 Comparisonof patientswith andwithoutportal vein resectionby follow-upcharacteristics
Follow up characteristics Overall cohort Without portal vein resection (n = 174) With portal vein resection (n = 47) Two-sided p-value
Follow-up (months) 12 ( 6–26) 12 (6–28) 11 (7–20) 0.52
Status at follow up (%)
NED 46 (21) 36 (21) 10 (21) 0.93
AWD 31 (14) 27 (16) 4 (9) 0.22
DOD 140 (63) 107 (48) 33 () 0.27
DOC 3 (1)
Lost of follow-up 1 (0.5)
Chemotherapy 126 (57) 98 (56) 27 (60) 0.94
Radiotherapy 3 (1) 2 (1) 1 (2) 0.61
Progression-free survival (months) 7 (4–16) 8 (4–15) 7 (4–16) 0.43
n = 2: bronchial carcinoma, n = 1: pneumonia; unless otherwise indicated, data are number (percentage); IQR interquartile range, NED No evidence of disease,
AWD Alive with disease, DOD Dead of disease, DOC Dead of other cause
Table 7 Uni- andmultivariatepredictors for survival (Cox
regression)
Predictor Univariate (HR/95% CI) Multivariate (HR/95% CI)
Sex 0.82 (95 CI 0.60–1.14) 1.09 (95 CI 0.71–1.68)
Age >70 years 1.31 (95 CI 0.92–1.86) 1.39 (95 CI 0.87–2.22)
Diabetes mellitus 1.01 (95 CI 0.75–1.56) 1.66 (95 CI 1.04–2.63)
Cardiovascular co-
morbidity
0.89 (95 CI 0.63–1.24) 0.62 (95 CI 0.39–0.99)
Preoperative symp-
tomatic
1.25 (95 CI 0.85–1.82) 0.93 (95 CI 0.59–1.48)
Preoperative weight
loss
1.45 (95 CI 1.00–2.09) 2.17 (95 CI 1.31–3.58)
Whipple procedure 0.56 (95 CI 0.39–0.79) 0.48 (95 CI 0.31–0.75)
Portal vein resection 1.18 (95 CI 0.79–1.76) 0.61 (95 CI 0.33–1.15)
Free margin (R0) 0.90 (95 CI 0.62–1.13) 0.78 (95 CI 0.50–1.22)
Vascular invasion 1.62 (95 CI 1.12–2.35) 2.03 (95 CI 1.10–3.76)
Lymphovascular
invasion
1.63 (95 CI 1.15–2.32) 1.59 (95 CI 1.02–2.45)
Perineural invasion 1.52 (95 CI 1.02–2.24) 1.53 (95 CI 0.95–2.47)
Organ infiltration 1.70 (95 CI 1.17–2.47) 1.04 (95 CI 0.63–1.71)
Tumor grading 1.79 (95 CI 1.35–2.37) 1.78 (95 CI 1.23–3.57)
Chemotherapy 0.16 (95 CI 0.05–0.53) 0.05 (95 CI 0.01–0.27)
CI Confidence interval, HR hazard ratio
Follow-up was complete in 99.5% and comprised
4393 patients–months of follow-up (for details Ta-
ble 6): 1-year and 5-year overall survival were 59
and 15% vs. 70 and 12% with and without PVR,
respectively (Log-rank: p = 0.25; Fig. 1).
For mid-term and long-term outcome, microvascu-
lar invasion (hazard ratio, HR 2.03, 95% CI 1.10–3.76),
preoperative weight loss (HR 2.17, 95% CI 1.31–3.58),
lymphovascular invasion (HR 1.59, 95% CI 1.03–2.45)
and tumor grading (HR 1.78 95% CI 1.23–2.57) were
independent predictors for mortality during follow-
up; but not portal vein resection (HR 0.61, 95%
CI 0.33–1.15); Whipple procedure (HR 0.48 95%
CI 0.01–0.75) and chemotherapy (HR 0.05 95% CI
0.01–0.27) were associated with lower risk of death
during follow-up (Table 7).
Discussion
As to our institutional long-term experience portal
vein resection represents a viable add-on option in
pancreatic surgery for locally advanced PDAC: com-
pared to patients without locally advanced disease,
short- and long-term results are acceptable without
significant differences.
In recent decades, infiltration of portal venous
and/or mesenteric venous branches has ceased to
be synonymous with inoperability [1, 9]. Portal vein
resection represents therefore the last option for pa-
tients with locally advanced disease to receive po-
tential curative surgery [1–5, 10–12] after diagnosis of
PDAC.
However, there is still an ongoing debate if pancre-
atic surgery with vascular resection and reconstruc-
tion increases the incidence of postoperative compli-
cations and morbidity [2–5, 9–12]. Our postoperative
complication rates according to Clavien and Dindo
(CDC) were 34 vs. 35% (p = 0.89), and 14 patients (5
vs. 11%; p = 0.18) died in-hospital, which are in line
with previously reported data for stand-alone pancre-
aticoduodenectomy [13, 14]. This particular finding
might be explained by the fact that our hepatobiliary
surgeons undergo extensive training in the vascular
surgical techniques. As a result, only two patients
required revision for bleeding; in one patient it was
probably due to development of a pancreatic fistula
with subsequent erosion hemorrhage; in the remain-
ing patient, the bleeding occurred within 24 h post-
operatively.
Further in contrast to others, all patients receive
continuous intravenous heparin in the early postoper-
ative period followed by platelet inhibitors in the late
postoperative period [15]. Indeed, only one patient
experienced portal vein thrombosis together with ab-
scess formation a few days after operation and an un-
favorable outcome. Computed tomography follow-up
has proven the patency of portal venous reconstruc-
tions in all discharged patients.
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Fig. 1 Kaplan–Meierplotofoverall survival inpatientswithand
withoutportal vein resection’
Current evidence is mixed regarding the risk of the
surgical procedure itself and postoperative morbidity
and mortality; although numerous publications pro-
pose different scoring systems to predict perioperative
mortality and morbidity for pancreatic resection, no
clinically established preoperative scoring system is
available at this point [16, 17]. As to our observation,
portal vein resection has no impact upon immediate
survival; an ASA Score >2 was the only independent
predictor for in-hospital mortality in logistic regres-
sion analysis (OR 10.66, 95% CI 1.24–91.30) has con-
firmed via bootstrap modelling. Indeed, all patients
but one who died during their intrahospital stay were
scored into ASA class 3 or 4. As to our opinion, this
well-established anesthesiologic score gives an excel-
lent picture of patient’s preoperative general health
conditions not only predicting the anesthesiologic risk
alone but also the perioperative risk for pancreatic re-
sections.
Median overall survival in our cohort did not dif-
fer between the cohorts with and without additional
portal vein resection. This finding is in line with other
publications in the field and would suggest that this
intervention is not worth the effort for locally ad-
vanced PDAC [10–12, 18]. However, from the onco-
logic point of view, it is the only chance for patients
with locally advanced PDAC to achieve similar survival
rates compared to those patients with lower staging
[10–12, 18]. As to our observation, besides extensive
preoperative weight loss (HR 2.17, 95% CI 1.31–3.58)
reflecting the advanced stage of disease, microvascu-
lar invasion reflecting the aggressive tumor biology
(HR 2.03, 95% CI 1.10–3.76) was the strongest inde-
pendent predictor for long-term survival.
To summarize, portal vein resection as an add-
on in pancreatic resection does not adversely im-
pact immediate, short- and long-term outcome in
locally advanced PDAC as preoperative risk factors
determine. The anesthesiologic ASA score gives an
excellent picture of patient’s preoperative general
health conditions not only predicting the anesthesi-
ologic risk alone but also the perioperative risk for
pancreatic resections. The feasibility of portal vein
resection should therefore be evaluated in every po-
tential candidate at risk.
Study limitations
Some limitations of the present study have to be ac-
knowledged. Although we could demonstrate that
a ASA Score >2 is a strong predictor of postopera-
tive outcome and not the surgical intervention itself,
sample size is modest when it comes to random vari-
ability, resulting in wide confidence intervals. To limit
this potential bias we performed a bootstrap analysis
confirming our initial results. However, our findings
from a retrospective single-center study will ideally
need confirmation in multicenter studies. Second, we
modified slightly the definitions of the international
study group (ISGPF) for postoperative complications
[19] due to the retrospective nature of study design:
We have only documented clinically significant pan-
creatic fistulas; a standardized analysis of drainage liq-
uid for amylase and lipase is not part of our routine
protocol. Furthermore, in our cohort, we did not as-
sess the incidence of delayed gastric emptying, as to
our institutional protocol, all patients receive a na-
sogastral tube and prokinetic drugs (metoclopramide
and/or domperidone) in the early postoperative pe-
riod. Residual confounding by patient management at
the operating theater and intensive care unit, however,
may be still present. Such confounders are impossi-
ble to control in an observational retrospective study
design. But considering overall death, our main end
point, this bias appears to be negligible as patient-re-
lated data were retrieved from a validated nationwide
Austrian Cancer Database [8].
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